GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Silo Wellness Inc (XCNQ:SILO) » Definitions » ROCE %

Silo Wellness (XCNQ:SILO) ROCE % : 0.00% (As of Jul. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Silo Wellness ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Silo Wellness's annualized ROCE % for the quarter that ended in Jul. 2023 was 0.00%.


Silo Wellness ROCE % Historical Data

The historical data trend for Silo Wellness's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silo Wellness ROCE % Chart

Silo Wellness Annual Data
Trend Oct20 Oct21 Oct22
ROCE %
- - -

Silo Wellness Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Silo Wellness ROCE % Calculation

Silo Wellness's annualized ROCE % for the fiscal year that ended in Oct. 2022 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Oct. 2022 )  (A: Oct. 2021 )(A: Oct. 2022 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Oct. 2022 )  (A: Oct. 2021 )(A: Oct. 2022 )
=-7.94/( ( (0.762 - 1.209) + (0.088 - 7.348) )/ 2 )
=-7.94/( (-0.447+-7.26)/ 2 )
=-7.94/-3.8535
=206.05 %

Silo Wellness's ROCE % of for the quarter that ended in Jul. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jul. 2023 )  (Q: Apr. 2023 )(Q: Jul. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jul. 2023 )  (Q: Apr. 2023 )(Q: Jul. 2023 )
=-1.14/( ( (0.085 - 2.198) + (0.083 - 2.414) )/ 2 )
=-1.14/( ( -2.113 + -2.331 )/ 2 )
=-1.14/-2.222
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Jul. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Silo Wellness  (XCNQ:SILO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Silo Wellness ROCE % Related Terms

Thank you for viewing the detailed overview of Silo Wellness's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Silo Wellness (XCNQ:SILO) Business Description

Traded in Other Exchanges
N/A
Address
200 Consumers Road, Suite 702, Toronto, ON, CAN, M2J 4R4
Silo Wellness Inc operates psychedelic clinics and develops legal functional mushroom consumer products. It is focused on health and wellness by developing and introducing psychedelic medicine to reduce trauma and increase performance by destigmatizing the active compounds in psychedelics and innovating ease of administration and ingestion.
Executives
Michael Hartman Director